http://www.usamci.com text only  

University of South Alabama

Page Content   Main Links

Contact Us   Links   Map & Driving Directions   Home   USA College of Medicine   USA Home
Gary A. Piazza, Ph.D.

Chief, Drug Discovery Research Center

Abraham A. Mitchell Distinguished Investigator

Professor of Oncologic Sciences and Pharmacology, University of South Alabama

Office:
USA Mitchell Cancer Institute
1660 Springhill Avenue
Mobile, AL. 36604
(251) 445-8412
gpiazza@usouthal.edu

Research Interests:
-Cancer chemopreventive activity of nonsteroidal anti-inflammatory drugs
-Phosphodiesterases, cyclic GMP signaling, and apoptosis
-High throughput screening and cellular imaging
-Cancer drug discovery and development

Honors, Professional Organizations, and Achievements:
-Member, American Association of Cancer Research, 1988-current
-Ad hoc NCI Reviewer, 1997-current
-Editorial Board, Molecular Cancer Therapeutics, 2003-current
-Editorial Board, International Journal for High Throughput Screening, 2009-current
-Howard C. Bailey Award of Excellence in Cancer Prevention, 2008

Education:
-Postdoctoral Fellow, Fox Chase Cancer Center, 1986-1988
-Ph.D., Pharmacology, University of Alabama at Birmingham, 1981-1986
-B.S., Biology and Psychology, Dominican University, 1977-1981

Professional Appointments:
-Research Assistant Oncologist, Brown University, Rhode Island Hospital, 1987-1989
-Staff Scientist, The Procter & Gamble Co., 1989-1994
-Senior Director of Biology, Cell Pathways Inc., 1994-2001
-Director, Department of Pharmacology, Institute for Drug Development, Adjunct Associate Professor of Pharmacology, Univ. of Texas, 2001-2003
-Manager, Cell Biology and Immunology Laboratories, Southern Research, 2003-2004
-Adjunct Associate Professor, Depart of Pharmacology and Toxicology, University of Alabama at Birmingham, 2004-2011
-Director, Southern Research Molecular Libraries Screening Center, 2004-2008
-Principal Scientist, Southern Research, Member, UAB Comprehensive Cancer Center, 2008-2011
-Adjunct Associate Professor, UAB Department of Biochemistry, 2009-2011
-Professor of Oncologic Sciences, Chief of Drug Discovery Research Center; University of South Alabama Mitchell Cancer Institute, 2011-current
-Professor of Pharmacology, University of South Alabama, 2011-current

Cancer drug discovery and development, cancer chemoprevention, NSAIDs, high throughput screening, colorectal and breast cancer.

1. Tinsley, H.N., Gary, B.D., Thaiparambil, J., Li, N., Lu, W., Li, Y., Maxuitenko, Y.Y. Keeton, A.B., and Piazza, G.A. (2010) “Colon tumor cell growth inhibitory activity of sulindac sulfide and other NSAIDs is associated with PDE5 inhibition” Cancer Prevention Research 3, 1303-1313.

2. Tinsley, H.N., Gary, B.D., Keeton, A.B., Zhang, W., Abadi, A.H., Reynolds, R.C., and Piazza, G.A. (2009) “Sulindac Sulfide Selectively Inhibits Growth and Induces Apoptosis of Human Breast Tumor Cells by PDE5 Inhibition, Elevation of cGMP, and Activation of PKG” Molecular Cancer Therapeutics 8: 3331-3340.

3. Piazza, G.A., Keeton, A.B., Tinsley, H.N., Gary, BD, Whitt, J.D., Mathew, B., Thaiparambil, J., Coward, L., Gorman, G., Li, Y., Sani, B., Hobrath, J.V., Maxuitenko, Y.Y. and Reynolds, R.C. (2009) “A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases, but Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity” Cancer Prevention Research, 2: 572-580.

4. Basler, J. W. and Piazza, G.A. (2004). “NSAIDs and cyclooxygenase-2 inhibitors for prostate cancer chemoprevention” J. Urol. 171(2):S59-S63.

5. Piazza, G.A., Thompson, W. J., Pamukcu, R., Whitehead, C., Li, L., Fetter, J., Gresh, B., Klein-Szanto, A., Farnell, D., Eto, I., and C. J., Grubbs (2001) “Exisulind inhibits rat urinary bladder tumorigenesis by cGMP mediated apoptosis” Cancer Research 61: 3961-3968.

6. Stoner, G.D., Budd, G.T., Ganapathi, R., DeYoung, B., Kresty, L.A., Church, J.M., Provencher, K., Pamukcu, R., Piazza, G., Hawk, E., Kelloff, G., Elson, P. and R. U. van Stolk (1999) “Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis” Adv. Exp. Med. Biol. 470: 45-53.

7. Thompson, W. J., Piazza, G.A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D., and R. Pamukcu (2000) “Exisulind induced apoptosis involves cGMP PDE Inhibition, PKG activation, and attenuated B-catenin” Cancer Research, 60: 3338 – 334.

8. Piazza, G.A., Rahm, A.K., Finn, T., Fryer, B., Li, H., Stoumen, A.L., Pamukcu, R. and D.J. Ahnen (1997) “Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites by a mechanism independent of cyclooxygenase inhibition, cell cycle arrest, or p53 mediation” Cancer Research 57: 2452 - 2459.

9. Piazza, G.A., Alberts, D.S., Hixson, L.J., Paranka, N.S., Bogert, C., Guillen, J.M., Brendel, K., Gross, P., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D.J. and R. Pamukcu (1997). “Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis without reducing prostaglandin levels” Cancer Research 57: 2909 - 2916.

10. Piazza, G.A., Kulchak, Rahm, A.L. Krutzsch, M., Sperl, G., Paranka, N.S., Gross, P.H, Brendel, K., Burt, R.W., Alberts, D.S., Pamukcu, R. and D.J. Ahnen (1995) “Antineoplastic drugs, sulindac sulfide and sulfone, inhibit cell growth by inducing apoptosis” Cancer Research, 55: 3110 - 3116.

Top of page

---

Usablenet Assistive is a UsableNet product. Usablenet Assistive Main Page.